Federated Hermes Inc. Trims Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Federated Hermes Inc. lessened its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 90.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,534 shares of the biotechnology company’s stock after selling 79,594 shares during the quarter. Federated Hermes Inc.’s holdings in Enanta Pharmaceuticals were worth $49,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $26,000. Intech Investment Management LLC acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $58,000. Wells Fargo & Company MN boosted its position in shares of Enanta Pharmaceuticals by 69.6% during the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company’s stock worth $91,000 after buying an additional 6,518 shares during the period. AlphaQuest LLC grew its stake in shares of Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 3,137 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Enanta Pharmaceuticals by 10.5% in the fourth quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 3,501 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Up 3.4 %

Shares of NASDAQ:ENTA opened at $5.10 on Friday. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $17.24. The firm’s 50 day moving average price is $6.30 and its 200 day moving average price is $7.48. The stock has a market cap of $108.80 million, a price-to-earnings ratio of -1.03 and a beta of 0.69.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. On average, equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Insider Activity

In related news, CEO Jay R. Luly bought 45,000 shares of the stock in a transaction dated Wednesday, February 12th. The stock was acquired at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the acquisition, the chief executive officer now owns 846,638 shares in the company, valued at approximately $4,817,370.22. This represents a 5.61 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 13.89% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on ENTA. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.